Daniela Pucciarelli
YOU?
Author Swipe
View article: Histone demethylase enzymes KDM5A and KDM5B modulate immune response by suppressing transcription of endogenous retroviral elements
Histone demethylase enzymes KDM5A and KDM5B modulate immune response by suppressing transcription of endogenous retroviral elements Open
Epigenetic factors, including lysine-specific demethylases such as the KDM5 paralogs KDM5A and KDM5B have been implicated in cancer and the regulation of immune responses. Here, we performed a comprehensive multiomic study in cells lacking…
View article: Supplementary Table 1 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Supplementary Table 1 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Table 1
View article: Fig. S1 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S1 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 1
View article: Fig. S4 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S4 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 4
View article: Data from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Data from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Loss of the tumor suppressor NF1 leads to activation of RAS effector pathways, which are therapeutically targeted by inhibition of mTOR (mTORi) or MEK (MEKi). However, therapeutic inhibition of RAS effectors leads to the development of dru…
View article: Fig. S8 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S8 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 8
View article: Supplementary Materials and Methods from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Supplementary Materials and Methods from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Materials and Methods
View article: Fig. S2 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S2 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 2
View article: Supplementary Table 3 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Supplementary Table 3 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Table 3
View article: Fig. S5 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S5 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 5
View article: Fig. S3 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S3 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 3
View article: Supplementary Table 2 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Supplementary Table 2 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Table 2
View article: Fig. S8 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S8 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 8
View article: Fig. S3 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S3 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 3
View article: Supplementary Materials and Methods from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Supplementary Materials and Methods from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Materials and Methods
View article: Fig. S6 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S6 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 6
View article: Fig. S5 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S5 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 5
View article: Fig. S4 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S4 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 4
View article: Fig. S6 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S6 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 6
View article: Fig. S7 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S7 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 7
View article: Data from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Data from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Loss of the tumor suppressor NF1 leads to activation of RAS effector pathways, which are therapeutically targeted by inhibition of mTOR (mTORi) or MEK (MEKi). However, therapeutic inhibition of RAS effectors leads to the development of dru…
View article: Supplementary Table 2 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Supplementary Table 2 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Table 2
View article: Supplementary Table 1 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Supplementary Table 1 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Table 1
View article: Fig. S2 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S2 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 2
View article: Fig. S7 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S7 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 7
View article: Supplementary Table 3 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Supplementary Table 3 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Table 3
View article: Fig. S1 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Fig. S1 from <i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Supplementary Figure 1
View article: <i>Nf1</i> -Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
<i>Nf1</i> -Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK Open
Loss of the tumor suppressor NF1 leads to activation of RAS effector pathways, which are therapeutically targeted by inhibition of mTOR (mTORi) or MEK (MEKi). However, therapeutic inhibition of RAS effectors leads to the development of dru…
A high-throughput screen of real-time ATP levels in individual cells reveals mechanisms of energy failure Open
Insufficient or dysregulated energy metabolism may underlie diverse inherited and degenerative diseases, cancer, and even aging itself. ATP is the central energy carrier in cells, but critical pathways for regulating ATP levels are not sys…
View article: Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib
Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib Open
A hypoxic microenvironment is one of the predominant reasons for incomplete response to melanoma treatment. Vemurafenib, which targets the mutated BRAF-V600 kinase, improves melanoma patient survival, however, resistance invariably develop…